<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Nutr.</journal-id>
<journal-title>Frontiers in Nutrition</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Nutr.</abbrev-journal-title>
<issn pub-type="epub">2296-861X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnut.2025.1498004</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Nutrition</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Multi-omics revealed that the postbiotic of hawthorn-probiotic alleviated constipation caused by loperamide in elderly mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Wei</surname> <given-names>Yu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn0004"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1730775/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Chen</surname> <given-names>Shuai</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="author-notes" rid="fn0004"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Ling</surname> <given-names>Ying</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn0004"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname> <given-names>Wei</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1344857/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huang</surname> <given-names>Yali</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/371018/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Guangzhou University of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Basic Medical Science College, Guangzhou University of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>The First Clinical Medical School, Guangzhou University of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Yunnan University of Chinese Medicine</institution>, <addr-line>Kunming</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0005">
<p>Edited by: Bwalya Angel Witika, Sefako Makgatho Health Sciences University, South Africa</p>
</fn>
<fn fn-type="edited-by" id="fn0006">
<p>Reviewed by: Pugazhendhi Srinivasan, University of Kansas Medical Center, United States</p>
<p>Aristote Buya, University of Kinshasa, Democratic Republic of Congo</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Yali Huang, <email>avonlii@163.com</email></corresp>
<corresp id="c002">Wei Wang, <email>wangwei16400@163.com</email></corresp>
<fn fn-type="equal" id="fn0004"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>02</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>12</volume>
<elocation-id>1498004</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>02</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2025 Wei, Chen, Ling, Wang and Huang.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Wei, Chen, Ling, Wang and Huang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract xml:lang="de">
<sec id="sec1">
<title>Background</title>
<p>Constipation is a prevalent and recurrent gastrointestinal disorder causing significant discomfort. However, current treatments often prove ineffective. Previous research indicates that the postbiotic derived from a combination of hawthorn and probiotics can alleviate constipation. This study aimed to investigate its mechanisms using loperamide-induced constipation in aged KM mice.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>Constipated mice were divided into groups receiving 10% lactulose (Y), hawthorn extract (S), probiotics (F), and the postbiotic of hawthorn-probiotic (FS). UPLC&#x2013;MS metabolomics identified constituents of F, S, and FS. Network pharmacological analysis identified targets affected by FS. RT-qPCR assessed target expression in mouse colons, along with IL-6 and IL-17A levels. Molecular docking with AutoDock Tools1.5.6 evaluated interactions between FS components and targets. ex vivo colonic organ culture and RT-qPCR assessed target changes. Molecular dynamics analysis further scrutinized interactions. Targeted metabolomics measured short-chain fatty acid levels in mouse stool.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>UPLC&#x2013;MS metabolomics revealed distinct profiles for F, S, and FS, with FS showing decreased toxic substances and increased beneficial ones compared to S. Network pharmacology identified 20 cross-targets of FS in constipation. RT-qPCR showed decreased NR1I2 and SULT1A1 and increased GLP-2r in FS-treated mice. Inflammatory cytokines IL-6 and IL-17A were also reduced. ex vivo colonic organ culture and molecular docking identified effective combinations such as TNF-Baicalin and AQP3-Quinacridone. RMSD, RMSF, and RG analyses indicated favorable interactions between small molecules and targets. Targeted metabolomics revealed differing short-chain fatty acid contents in feces among groups.</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>The postbiotic of hawthorn-probiotic alleviates constipation by regulating intestinal water and sodium metabolism, maintaining the intestinal barrier and gut flora, promoting epithelial cell proliferation, reducing inflammatory responses, and improving short-chain fatty acid metabolism.</p>
</sec>
</abstract>
<kwd-group>
<kwd>postbiotic</kwd>
<kwd>hawthorn</kwd>
<kwd>probiotic</kwd>
<kwd>constipation</kwd>
<kwd>inflammation</kwd>
<kwd>intestinal microenvironment</kwd>
</kwd-group>
<contract-num rid="cn1">31700288</contract-num>
<contract-sponsor id="cn1">Chinese National Natural Science Foundation</contract-sponsor>
<counts>
<fig-count count="9"/>
<table-count count="7"/>
<equation-count count="0"/>
<ref-count count="31"/>
<page-count count="14"/>
<word-count count="6970"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Nutrition and Metabolism</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<label>1</label>
<title>Introduction</title>
<p>Chronic senile constipation is one of the common digestive system problems in the elderly (&#x003E;65-70&#x202F;years) (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref2">2</xref>), and its incidence increases with the increase of age (<xref ref-type="bibr" rid="ref3">3</xref>). This type of constipation can be caused by a variety of factors, including lifestyle factors, dietary habits, side effects of medications, neuromuscular dysfunction, and digestive disorders (<xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref5">5</xref>). In addition to traditional drug treatment and dietary changes, some new treatment methods are gradually attracting attention, such as probiotics, prebiotics and post-biologics, which can relieve constipation by regulating intestinal flora and improving intestinal function (<xref ref-type="bibr" rid="ref6 ref7 ref8 ref9 ref10 ref11 ref12">6&#x2013;12</xref>).</p>
<p>Our previous research efforts have identified the potential of hawthorn-probiotic post-biotics in alleviating constipation (<xref ref-type="bibr" rid="ref13">13</xref>). We found that postbiotic of hawthorn-probiotic exerts remarkable effects on constipation by regulating water and sodium metabolism, repairing intestinal barrier, relieving inflammation, and restoring microflora structure (<xref ref-type="bibr" rid="ref13">13</xref>). Recently we make some progress on the postbiotic of hawthorn-probiotic metabolites and targets for constipation. We think these might offer a promising therapy for constipation.</p>
</sec>
<sec sec-type="materials|methods" id="sec6">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec7">
<label>2.1</label>
<title>Materials</title>
<sec id="sec8">
<label>2.1.1</label>
<title>Metabolite</title>
<p>
<table-wrap position="anchor" id="tab1">
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Pubchem CID</th>
<th align="left" valign="top">Metabolite name</th>
<th align="left" valign="top">Source</th>
<th align="center" valign="top">CAS number</th>
<th align="center" valign="top">Purity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">13976</td>
<td align="left" valign="middle">Quinacridone</td>
<td align="left" valign="middle" rowspan="11">Chengdu Must Bio-Technology Co., Ltd.</td>
<td align="center" valign="middle">1047-16-1</td>
<td align="center" valign="middle">98%</td>
</tr>
<tr>
<td align="left" valign="middle">5282151</td>
<td align="left" valign="middle">vitexin-2&#x2033;-o-rhamnoside</td>
<td align="center" valign="middle">64820-99-1</td>
<td align="center" valign="middle">HPLC&#x2265;98%</td>
</tr>
<tr>
<td align="left" valign="middle">9830628</td>
<td align="left" valign="middle">L-Isoleucine</td>
<td align="center" valign="middle">73-32-5</td>
<td align="center" valign="middle">99%</td>
</tr>
<tr>
<td align="left" valign="middle">64982</td>
<td align="left" valign="middle">Baicalin</td>
<td align="center" valign="middle">21967-41-9</td>
<td align="center" valign="middle">HPLC&#x2265;98%</td>
</tr>
<tr>
<td align="left" valign="middle">60198</td>
<td align="left" valign="middle">Exemestane</td>
<td align="center" valign="middle">107868-30-4</td>
<td align="center" valign="middle">98%</td>
</tr>
<tr>
<td align="left" valign="middle">5281643</td>
<td align="left" valign="middle">Hyperoside</td>
<td align="center" valign="middle">482-36-0</td>
<td align="center" valign="middle">HPLC&#x2265;98%</td>
</tr>
<tr>
<td align="left" valign="middle">5280343</td>
<td align="left" valign="middle">Quercetin</td>
<td align="center" valign="middle">117-39-5</td>
<td align="center" valign="middle">HPLC&#x2265;98%</td>
</tr>
<tr>
<td align="left" valign="middle">5280443</td>
<td align="left" valign="middle">Apigenin</td>
<td align="center" valign="middle">520-36-5</td>
<td align="center" valign="middle">HPLC&#x2265;98%</td>
</tr>
<tr>
<td align="left" valign="middle">8679</td>
<td align="left" valign="middle">N-Phenyl-2-naphthylamine</td>
<td align="center" valign="middle">135-88-6</td>
<td align="center" valign="middle">98%</td>
</tr>
<tr>
<td align="left" valign="middle">5280961</td>
<td align="left" valign="middle">Genistein</td>
<td align="center" valign="middle">446-72-0</td>
<td align="center" valign="middle">97%</td>
</tr>
<tr>
<td align="left" valign="middle">5281708</td>
<td align="left" valign="middle">Daidzein</td>
<td align="center" valign="middle">486-66-8</td>
<td align="center" valign="middle">HPLC&#x2265;98%</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
</sec>
<sec id="sec9">
<label>2.1.2</label>
<title>Short chain fatty acids standard</title>
<p>
<table-wrap position="anchor" id="tab2">
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Name</th>
<th align="center" valign="top">CAS number</th>
<th align="center" valign="top">Molecular formula</th>
<th align="center" valign="top">Molecular weight</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Acetic acid</td>
<td align="center" valign="middle">64-19-7</td>
<td align="center" valign="middle">C<sub>2</sub>H<sub>4</sub>O<sub>2</sub></td>
<td align="center" valign="middle">60.05</td>
</tr>
<tr>
<td align="left" valign="middle">Propionic acid</td>
<td align="center" valign="middle">79-09-4</td>
<td align="center" valign="middle">C<sub>3</sub>H<sub>6</sub>O<sub>2</sub></td>
<td align="center" valign="middle">74.08</td>
</tr>
<tr>
<td align="left" valign="middle">Isobutyric acid</td>
<td align="center" valign="middle">79-31-2</td>
<td align="center" valign="middle">C<sub>4</sub>H<sub>8</sub>O<sub>2</sub></td>
<td align="center" valign="middle">88.11</td>
</tr>
<tr>
<td align="left" valign="middle">Butyric Acid</td>
<td align="center" valign="middle">107-92-6</td>
<td align="center" valign="middle">C<sub>4</sub>H<sub>8</sub>O<sub>2</sub></td>
<td align="center" valign="middle">88.11</td>
</tr>
<tr>
<td align="left" valign="middle">Valeric acid</td>
<td align="center" valign="middle">109-52-4</td>
<td align="center" valign="middle">C<sub>5</sub>H<sub>10</sub>O<sub>2</sub></td>
<td align="center" valign="middle">102.13</td>
</tr>
<tr>
<td align="left" valign="middle">Isovaleric acid</td>
<td align="center" valign="middle">503-74-2</td>
<td align="center" valign="middle">C<sub>5</sub>H<sub>10</sub>O<sub>2</sub></td>
<td align="center" valign="middle">102.13</td>
</tr>
<tr>
<td align="left" valign="middle">Hexanoic acid</td>
<td align="center" valign="middle">142-62-1</td>
<td align="center" valign="middle">C<sub>6</sub>H<sub>12</sub>O<sub>2</sub></td>
<td align="center" valign="middle">116.16</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
</sec>
<sec id="sec10">
<label>2.1.3</label>
<title>Chemicals</title>
<p>
<table-wrap position="anchor" id="tab3">
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Name</th>
<th align="left" valign="top">Source</th>
<th align="left" valign="top">Cat. number</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Methanol, LC&#x2013;MS Grade</td>
<td align="left" valign="middle">CNW</td>
<td align="left" valign="middle">CAEQ-4-000306-4000</td>
</tr>
<tr>
<td align="left" valign="middle">Acetonitrile, LC&#x2013;MS Grade</td>
<td align="left" valign="middle">CNW</td>
<td align="left" valign="middle">CAEQ-4-000308-4000</td>
</tr>
<tr>
<td align="left" valign="middle">Acetice Acid, LC&#x2013;MS Grade</td>
<td align="left" valign="middle">CNW</td>
<td align="left" valign="middle">CAEQ-4-000319-0050</td>
</tr>
<tr>
<td align="left" valign="middle">Ammonium Acetate, LC&#x2013;MS Grade</td>
<td align="left" valign="middle">CNW</td>
<td align="left" valign="middle">CAEQ-4-000314-0050</td>
</tr>
<tr>
<td align="left" valign="middle">Krebs-Ringer Buffer</td>
<td align="left" valign="top">Solarbio</td>
<td align="left" valign="middle">G0430-500&#x202F;ml</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
</sec>
<sec id="sec11">
<label>2.1.4</label>
<title>Critical commercial assays</title>
<p>
<table-wrap position="anchor" id="tab4">
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Name</th>
<th align="left" valign="top">Source</th>
<th align="left" valign="top">Cat. number</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">RNAiso Plus</td>
<td align="left" valign="top">Vazyme</td>
<td align="left" valign="top">R401</td>
</tr>
<tr>
<td align="left" valign="top">SweScript RT I First Strand cDNA Synthesis Kit</td>
<td align="left" valign="top">Servicebio</td>
<td align="left" valign="top">G3330</td>
</tr>
<tr>
<td align="left" valign="top">2X Universal Blue SYBR Green qPCR Master Mix</td>
<td align="left" valign="top">Servicebio</td>
<td align="left" valign="top">G3326</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
</sec>
<sec id="sec12">
<label>2.1.5</label>
<title>Software and Algorithms</title>
<p>
<table-wrap position="anchor" id="tab5">
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="left" valign="top">R version3.6.3</td>
<td align="left" valign="top">The R Foundation</td>
<td align="left" valign="top">N/A</td>
</tr>
<tr>
<td align="left" valign="top">SIMCA</td>
<td align="left" valign="top">Umetrics AB</td>
<td align="left" valign="top">N/A</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
</sec>
</sec>
<sec id="sec13">
<label>2.2</label>
<title>Preparation and metabolic constituents of hawthorn-probiotic</title>
<sec id="sec14">
<label>2.2.1</label>
<title>Preparation of hawthorn aqueous extract and postbiotic</title>
<p>According to the preparation process of the previous study (<xref ref-type="bibr" rid="ref13">13</xref>), the sequence of <italic>Lactobacillus paracasei</italic> is shown in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S1</xref>. We prepared three groups of fermentation liquid required for the experiment [hawthorn group (S), probiotic group (F) and postbiotic of hawthorn-probiotic group (FS)].</p>
</sec>
<sec id="sec15">
<label>2.2.2</label>
<title>Metabolite extraction</title>
<p>The collected samples were thawed on ice, and metabolite were extracted with 80% methanol Buffer. Briefly, 100&#x202F;&#x03BC;l of sample was extracted with 400 &#x03BC;l of precooled methanol. The extraction mixture was then stored in 30 min at &#x2212;20&#x00B0;C. After centrifugation at 20,000<italic>g</italic> for 15 min, the supernatants were transferred into new tube to and vacuum dried. The samples were redissolved with 100&#x202F;&#x03BC;l 80% methanol and stored at &#x2212;80&#x00B0;C prior to the LC-MS analysis. In addition, pooled QC samples were also prepared by combining 10&#x202F;&#x03BC;l of each extraction mixture (<xref ref-type="bibr" rid="ref14">14</xref>).</p>
</sec>
<sec id="sec16">
<label>2.2.3</label>
<title>High performance liquid chromatography</title>
<p>All samples were acquired by the LC&#x2013;MS system followed machine orders. Firstly, all chromatographic separations were performed using a Vanquish Flex UPLC system (Thermo Fisher Scientific, Bremen, Germany). An ACQUITY UPLC T3 column (100&#x202F;mm&#x002A;2.1&#x202F;mm, 1.8&#x202F;&#x03BC;m, Waters, Milford, USA) was used for the reversed phase separation. The column oven was maintained at 40&#x00B0;C. The flow rate was 0.3&#x202F;mL/min and the mobile phase consisted of solvent A (water, 5&#x202F;mM ammonium acetate and 5&#x202F;mM acetic acid) and solvent B (Acetonitrile). Gradient elution conditions were set as follows: 0&#x202F;~&#x202F;0.8&#x202F;min, 2% B; 0.8&#x202F;~&#x202F;2.8&#x202F;min, 2 to 70% B; 2.8&#x202F;~&#x202F;5.3&#x202F;min, 70 to 90% B; 5.3&#x202F;~&#x202F;5.9&#x202F;min, 90 to 100% B; 5.9&#x202F;~&#x202F;7.5&#x202F;min, 100% B; 7.5&#x202F;~&#x202F;7.6&#x202F;min, 100 to 2% B; 7.6&#x202F;~&#x202F;10&#x202F;min, 2%B.</p>
</sec>
<sec id="sec17">
<label>2.2.4</label>
<title>High resolution mass spectrometry</title>
<p>A high-resolution tandem mass spectrometer Q-Exactive (Thermo Scientific) was used to detect metabolites eluted from the column. The Q-Exactive was operated in both positive and negative ion modes. Precursor spectra (70&#x2013;1,050&#x202F;m/z) were collected at 70,000 resolution to hit an AGC target of 3e6. The maximum inject time was set to 100&#x202F;ms. A top 3 configuration to acquire data was set in DDA mode. Fragment spectra were collected at 17,500 resolution to hit an AGC target of 1e5 with a maximum inject time of 50&#x202F;ms. In order to evaluate the stability of the LC&#x2013;MS during the whole acquisition, a quality control sample (Pool of all samples) was acquired after every 10 samples.</p>
</sec>
</sec>
<sec id="sec18">
<label>2.3</label>
<title>The analysis of the online pharmacology of post-biologics</title>
<sec id="sec19">
<label>2.3.1</label>
<title>The collection and arrangement of the action target of the postbiotic of hawthorn-probiotic and constipation</title>
<p>TCMID, Batman and Herb databases were used to search for the corresponding target of the active ingredients of the postbiotic of hawthorn-probiotic.</p>
<p>No corresponding target ingredients were found for the time being, and Swisstargetprediction platform was used to predict the target. The results of these database searches would overlap. Excel software was used to remove duplicate targets and integrate, and the target name was imported into the Uniport database, and the type was set as &#x201C;<italic>Homo sapiens</italic>&#x201D; to obtain the corresponding gene name.</p>
<p>Disease targets by using &#x201C;Constipation&#x201D; as key word were searched and extracted by TTD, Herb and Omim databases.</p>
</sec>
<sec id="sec20">
<label>2.3.2</label>
<title>Analysis of Venn diagram and construction of target network of &#x201C;TCM active ingredients-intersection target-disease&#x201D;</title>
<p>Venny2.10 platform was used to analyze the target of drug action and the target of intestinal adhesion disease, and statistical intersection was formed and Wayne diagram was formed. The collected data were compiled and imported into Cytoscape3.91 software to construct the target network diagram of &#x201C;TCM active ingredients&#x2014;intersection targets&#x2014;diseases.&#x201D;</p>
</sec>
<sec id="sec21">
<label>2.3.3</label>
<title>PPI protein interaction network construction</title>
<p>The intersection targets were imported into the String platform and the type was defined as &#x201C;<italic>Homo sapiens</italic>&#x201D; to analyze and construct the PPI protein interaction network.</p>
</sec>
<sec id="sec22">
<label>2.3.4</label>
<title>Molecular docking</title>
<p>Acquisition and preprocessing of receptor proteins and compounds: The three-dimensional (3D) structures of the receptor proteins were obtained by jointly utilizing the UniProt<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> and PDB<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref> databases. The protein structures were then processed using PyMOL version 2.3.0 to remove crystallographic water, irrelevant protein chains, and the original ligands. The 3D structures of the compounds were retrieved from the PubChem database,<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref> and the molecular structures were optimized using the MMFF94 force field with Open Babel3.1.1, resulting in the lowest energy conformation of the molecule. Detailed information about the compounds is provided in <xref ref-type="table" rid="tab6">Table 1</xref> at the end of the manuscript.</p>
<table-wrap position="float" id="tab6">
<label>Table 1</label>
<caption>
<p>The primers&#x2019; sequences of genes in this study.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Genes</th>
<th align="left" valign="top">Sequence of primers</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="bottom" rowspan="2"><italic>ABCB1B</italic></td>
<td align="left" valign="bottom">5&#x2032;-AGTGTTAAAGGGGCGATGGG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-GACTCCTGTCCCGAGGTTTG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom" rowspan="2"><italic>NR1L2</italic></td>
<td align="left" valign="bottom">5&#x2032;-AGACCTGAGGAGAGCTGGAG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-TTGGCCTTGTCCCCACATAC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom" rowspan="2"><italic>NR1L3</italic></td>
<td align="left" valign="bottom">5&#x2032;-GTCCATGGGTTCCAGTACGAG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-TAACTCCGGGTCTGTCAGGG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>SULT1A1 (ST1A1)</italic></td>
<td align="left" valign="bottom">5&#x2032;-AGGTGATCTACGTTGCCCGAAATG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-GTACCACGACCCATAGGACACTTTC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>IL-6</italic></td>
<td align="left" valign="bottom">5&#x2032;-GGCGGATCGGATGTTGTGAT-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-GGACCCCAGACAATCGGTTG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>IL-17A</italic></td>
<td align="left" valign="bottom">5&#x2032;-TGATGCTGTTGCTGCTGCTGAG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-CACATTCTGGAGGAAGTCCTTGGC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>GLP-2r</italic></td>
<td align="left" valign="bottom">5&#x2032;-TTCTGCCTCCTGCCGCTCTG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-AGTCCTTCAACCAGCAACCACAAG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>AQP-3</italic></td>
<td align="left" valign="bottom">5&#x2032;-CGCTGGTGTCTTCGTGTACC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-TGTGGGCCAGCTTCACATTC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>ENAC-&#x03B3; (SCNN1G)</italic></td>
<td align="left" valign="bottom">5&#x2032;-TGAGTGACCTCCTGACTGACTTGG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-GAAATCTGGGTGGTGTGCCTTCC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>TNF-&#x03B1;</italic></td>
<td align="left" valign="bottom">5&#x2032;-GGAACACGTCGTGGGATAATG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-GGCAGACTTTGGATGCTTCTT-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="2"><italic>&#x03B2;-actin</italic></td>
<td align="left" valign="bottom">5&#x2032;-CGTTGACATCCGTAAAGACC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="bottom">5&#x2032;-AACAGTCCGCCTAGAAGCAC-3&#x2032;</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Molecular Docking: Hydrogen atoms were added to both the receptor proteins and the compounds using AutoDock Tools1.5.6. The rotatable bonds of the compounds were identified, and the structures were saved in pdbqt format. The docking grid parameters were set using the Grid module. Receptor protein details and docking range parameters provided in <xref ref-type="table" rid="tab7">Table 2</xref>. The docking protocol was set to semi-flexible docking, employing the Lamarckian genetic algorithm for docking with an exhaustiveness value of 25. Molecular docking was performed using AutoDock Vina 1.2.0 to obtain the binding free energy and docking result files.</p>
<table-wrap position="float" id="tab7">
<label>Table 2</label>
<caption>
<p>The top 10 metabolites of each protein by binding energy.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Protein name</th>
<th align="center" valign="top">Pubchem CID</th>
<th align="left" valign="top">Metabolite name</th>
<th align="center" valign="top">Binding energy</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">AQP3</td>
<td align="center" valign="top">13976</td>
<td align="left" valign="middle">Quinacridone</td>
<td align="center" valign="middle">&#x2212;9.3</td>
</tr>
<tr>
<td align="left" valign="top">AQP3</td>
<td align="center" valign="top">5282151</td>
<td align="left" valign="middle">Vitexin-2-O-rhamnoside</td>
<td align="center" valign="middle">&#x2212;9.3</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="top">9830628</td>
<td align="left" valign="middle">L-Isoleucine</td>
<td align="center" valign="middle">&#x2212;9.2</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="top">64982</td>
<td align="left" valign="middle">Baicalin</td>
<td align="center" valign="middle">&#x2212;9.1</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="middle">6198</td>
<td align="left" valign="middle">EXEMESTANE</td>
<td align="center" valign="middle">&#x2212;8.5</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="middle">441793</td>
<td align="left" valign="middle">Eurycomalactone</td>
<td align="center" valign="middle">&#x2212;8.4</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="middle">5281643</td>
<td align="left" valign="middle">Hyperoside</td>
<td align="center" valign="middle">&#x2212;8.4</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="middle">76005853</td>
<td align="left" valign="middle">6-[4-(3-Chlorophenyl)-1-Piperazinyl]-3-Cyclohexyl-2</td>
<td align="center" valign="middle">&#x2212;8.4</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="middle">6030</td>
<td align="left" valign="middle">Uridine 5&#x2032;-Monophosphate</td>
<td align="center" valign="middle">&#x2212;8.3</td>
</tr>
<tr>
<td align="left" valign="middle">AQP3</td>
<td align="center" valign="middle">13653606</td>
<td align="left" valign="middle">Furanylfentanyl</td>
<td align="center" valign="middle">&#x2212;8.2</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">64,982</td>
<td align="left" valign="middle">Baicalin</td>
<td align="center" valign="middle">&#x2212;8.4</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">13976</td>
<td align="left" valign="middle">Quinacridone</td>
<td align="center" valign="middle">&#x2212;7.9</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">441793</td>
<td align="left" valign="middle">Eurycomalactone</td>
<td align="center" valign="middle">&#x2212;7.9</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">60198</td>
<td align="left" valign="middle">EXEMESTANE</td>
<td align="center" valign="middle">&#x2212;7.9</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">76005853</td>
<td align="left" valign="middle">6-[4-(3-Chlorophenyl)-1-Piperazinyl]-3-Cyclohexyl-2</td>
<td align="center" valign="middle">&#x2212;7.6</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">9830628</td>
<td align="left" valign="middle">L-Isoleucine</td>
<td align="center" valign="middle">&#x2212;7.5</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">5280343</td>
<td align="left" valign="middle">Quercetin</td>
<td align="center" valign="middle">&#x2212;7.3</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">5282151</td>
<td align="left" valign="middle">Vitexin-2-O-rhamnoside</td>
<td align="center" valign="middle">&#x2212;7.3</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">13653606</td>
<td align="left" valign="middle">Furanylfentanyl</td>
<td align="center" valign="middle">&#x2212;7</td>
</tr>
<tr>
<td align="left" valign="middle">IL17A</td>
<td align="center" valign="middle">5280443</td>
<td align="left" valign="middle">Apigenin</td>
<td align="center" valign="middle">&#x2212;7</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">13976</td>
<td align="left" valign="middle">Quinacridone</td>
<td align="center" valign="middle">&#x2212;8.7</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">5282151</td>
<td align="left" valign="middle">Vitexin-2-O-rhamnoside</td>
<td align="center" valign="middle">&#x2212;8.3</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">64982</td>
<td align="left" valign="middle">Baicalin</td>
<td align="center" valign="middle">&#x2212;8.2</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">13653606</td>
<td align="left" valign="middle">Furanylfentanyl</td>
<td align="center" valign="middle">&#x2212;8.1</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">5280448</td>
<td align="left" valign="middle">Calycosin</td>
<td align="center" valign="middle">&#x2212;8</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">9830628</td>
<td align="left" valign="middle">L-Isoleucine</td>
<td align="center" valign="middle">&#x2212;8</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">60198</td>
<td align="left" valign="middle">EXEMESTANE</td>
<td align="center" valign="middle">&#x2212;7.9</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">441793</td>
<td align="left" valign="middle">Eurycomalactone</td>
<td align="center" valign="middle">&#x2212;7.7</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">5281643</td>
<td align="left" valign="middle">Hyperoside</td>
<td align="center" valign="middle">&#x2212;7.7</td>
</tr>
<tr>
<td align="left" valign="middle">SCNN1G</td>
<td align="center" valign="middle">76005853</td>
<td align="left" valign="middle">6-[4-(3-Chlorophenyl)-1-Piperazinyl]-3-Cyclohexyl-2</td>
<td align="center" valign="middle">&#x2212;7.7</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">8679</td>
<td align="left" valign="middle">N-Phenyl-2-naphthylamine</td>
<td align="center" valign="middle">&#x2212;11.2</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">5280443</td>
<td align="left" valign="middle">Apigenin</td>
<td align="center" valign="middle">&#x2212;11.1</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">5280343</td>
<td align="left" valign="middle">Quercetin</td>
<td align="center" valign="middle">&#x2212;10.7</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">15394713</td>
<td align="left" valign="middle">(2S,4R)-4-(9H-Pyrido[3,4-b]indol-1-yl)-1,2,4-butanetriol</td>
<td align="center" valign="middle">&#x2212;10.4</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">5280961</td>
<td align="left" valign="middle">Genistein</td>
<td align="center" valign="middle">&#x2212;10.1</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">6030</td>
<td align="left" valign="middle">Uridine 5&#x2032;-Monophosphate</td>
<td align="center" valign="middle">&#x2212;10</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">10107340</td>
<td align="left" valign="middle">N-Acetyl Retigabine</td>
<td align="center" valign="middle">&#x2212;9.9</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">9830628</td>
<td align="left" valign="middle">L-Isoleucine</td>
<td align="center" valign="middle">&#x2212;9.9</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">5281708</td>
<td align="left" valign="middle">Daidzein</td>
<td align="center" valign="middle">&#x2212;9.8</td>
</tr>
<tr>
<td align="left" valign="middle">SULT1A1</td>
<td align="center" valign="middle">575067</td>
<td align="left" valign="middle">5-Hydroxy-4-methoxy-6-(2-phenylethyl)-5,6-dihydro-2H-pyran-2-one</td>
<td align="center" valign="middle">&#x2212;9.8</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">64982</td>
<td align="left" valign="middle">Baicalin</td>
<td align="center" valign="middle">&#x2212;10.2</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">13653606</td>
<td align="left" valign="middle">Furanylfentanyl</td>
<td align="center" valign="middle">&#x2212;9.7</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">6351946</td>
<td align="left" valign="middle">L-prolyl-L-phenylalanine</td>
<td align="center" valign="middle">&#x2212;9.7</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">263426</td>
<td align="left" valign="middle">(1xi,3S)-1,2,3,4-Tetrahydro-1-methyl-beta-carboline-1,3-dicarboxylic acid</td>
<td align="center" valign="middle">&#x2212;9.4</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">5280448</td>
<td align="left" valign="middle">Calycosin</td>
<td align="center" valign="middle">&#x2212;9.4</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">78651</td>
<td align="left" valign="middle">2-Amino-4-methylbenzophenone</td>
<td align="center" valign="middle">&#x2212;9.4</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">8679</td>
<td align="left" valign="middle">N-Phenyl-2-naphthylamine</td>
<td align="center" valign="middle">&#x2212;9.4</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">5281708</td>
<td align="left" valign="middle">Daidzein</td>
<td align="center" valign="middle">&#x2212;9.3</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">5280443</td>
<td align="left" valign="middle">Apigenin</td>
<td align="center" valign="middle">&#x2212;9.2</td>
</tr>
<tr>
<td align="left" valign="middle">TNF</td>
<td align="center" valign="middle">73530</td>
<td align="left" valign="middle">Tetrahydroharman-3-carboxylic acid</td>
<td align="center" valign="middle">&#x2212;9.2</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">9830628</td>
<td align="left" valign="middle">L-Isoleucine</td>
<td align="center" valign="middle">&#x2212;8.8</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">5282151</td>
<td align="left" valign="middle">Vitexin-2-O-rhamnoside</td>
<td align="center" valign="middle">&#x2212;8.7</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">64982</td>
<td align="left" valign="middle">Baicalin</td>
<td align="center" valign="middle">&#x2212;8.7</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">441793</td>
<td align="left" valign="middle">Eurycomalactone</td>
<td align="center" valign="middle">&#x2212;8.4</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">13976</td>
<td align="left" valign="middle">Quinacridone</td>
<td align="center" valign="middle">&#x2212;8.2</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">263426</td>
<td align="left" valign="middle">(1xi,3S)-1,2,3,4-Tetrahydro-1-methyl-beta-carboline-1,3-dicarboxylic acid</td>
<td align="center" valign="middle">&#x2212;8.2</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">5281643</td>
<td align="left" valign="middle">Hyperoside</td>
<td align="center" valign="middle">&#x2212;8.1</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">60198</td>
<td align="left" valign="middle">EXEMESTANE</td>
<td align="center" valign="middle">&#x2212;8</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">580443</td>
<td align="left" valign="middle">Apigeni</td>
<td align="center" valign="middle">&#x2212;7.9</td>
</tr>
<tr>
<td align="left" valign="middle">GLP-2r</td>
<td align="center" valign="middle">76005853</td>
<td align="left" valign="middle">6-[4-(3-Chlorophenyl)-1-Piperazinyl]-3-Cyclohexyl-2</td>
<td align="center" valign="middle">&#x2212;7.9</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec23">
<label>2.3.5</label>
<title>Molecular dynamics simulation</title>
<p>The Gromacs2020 software was used to simulate the molecular dynamics of the protein-compound complexes obtained by molecular docking. Amber14sb was selected as the protein force field, Gaff2 as the coordination force field, TIP3P water model was selected to add solvent to the protein ligand system and establish a water box with periodic boundary of 1.2&#x202F;nm. Charges in the equilibrium system of sodium and chloride ions were added to restore the real experimental environment as far as possible. Prior to the formal kinetic simulation, the complex was minimized for 50,000 steps using a conjugate gradient algorithm, followed by a further equilibrium system of 100&#x202F;ps using an isothermal (310&#x202F;K) system (NVT) and an isobaric (1 standard atmosphere) system (NPT), and finally a molecular dynamics simulation of 100 Ns at normal temperature and pressure.</p>
<p>Analysis of molecular dynamics simulation results:</p>
<p>At present, the semi-flexible docking used for molecular docking cannot take into account the flexibility of protein structure. In order to further prove the degree and stability of binding between compounds and proteins, molecular dynamics simulations of 100&#x202F;ns were performed for each group of docking results. We analyze the root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of rotation (Rg) and Gibbs free energy landscape in the molecular dynamics simulation trajectory of the complex.</p>
</sec>
</sec>
<sec id="sec24">
<label>2.4</label>
<title>Animals and groups</title>
<p>240-day-old, male KM mice obtained from the Guangzhou Regal Biotechnology Co., Ltd., SCXK [Yue] 2018&#x2013;0182, SYXK [Yue] 2021&#x2013;0059) were pair-housed in plastic cages in a temperature-controlled (25&#x202F;&#x00B1;&#x202F;2&#x00B0;C) colony room under a 12/12-h light/dark cycle, with free access to food and water. The aged KM male mice were administrated with distilled water throughout the whole course and 6 mice were grouped as the normal controls without any other intervention(N). The rest mice were treated with 5&#x202F;mg/kg loperamide (imodium, SOURCE: Xian Janssen Pharmaceutical Ltd. IDENTIFIER: LGJ0549.) for 1&#x202F;week and randomly divided into model group (M), positive drug group (Y), hawthorn group (S), probiotic group (F) and postbiotic of hawthorn-probiotic group (FS). Mice in Y group were intragastrically treated with 10% lactulose (0.2&#x202F;ml/day/per mouse), S group with 1&#x202F;g/ml pure hawthorn solution (0.2&#x202F;ml/day/per mouse), F group with <italic>Lactobacillus paracasei</italic> supernatant (0.2&#x202F;ml/day/per mouse) and FS group with postbiotic of hawthorn-probiotic (0.2&#x202F;ml/day/per mouse) for another week.</p>
<p>The inclusion criteria were normal development, appropriate age, and weight. The exclusion criteria were abnormal development, inappropriate age, or weight. Any single criterion not met resulted in exclusion. Grouping was conducted randomly according to cage order, and blind method was employed to select one individual for gavage. The experimenter assigned a number to the gavage material, and the individual performing the gavage administered it based on the assigned number. During the observation period, the condition of all KM mice was closely monitored. If any adverse reactions were detected, the gavage was immediately discontinued. However, throughout the entire experiment, the mice remained in good health and no abnormalities were observed.</p>
<p>These KM mice were sacrificed after anesthesia with pentobarbital sodium. The structure of colon, and fecal metabolite of mice were determined. All experimental protocols were approved by the Animal Center, Guangzhou University of Chinese Medicine.</p>
</sec>
<sec id="sec25">
<label>2.5</label>
<title>RNA isolation and quantitative analysis</title>
<p>RNA was extracted from colon tissue using RNAiso Plus according to the instructions. Then, cDNA was obtained using the ImProm-II&#x2122; Reverse Transcription System (Promega) and RT-qPCR was carried out with custom designed oligonucleotides using the SweScript RT I First Strand cDNA Synthesis Kit and 2X Universal Blue SYBR Green qPCR Master Mix in a total volume of 20&#x202F;&#x03BC;l: 95&#x00B0;C for 1&#x202F;min and 40&#x202F;cycles of denaturation (95&#x00B0;C for 15&#x202F;s) and extension (60&#x00B0;C for 1&#x202F;min). Experiments were performed in triplicates. Following amplification, dissociation curve analyses were performed to confirm the amplicon specificity for each PCR run. The relative level of gene expression in mouse colon tissue was normalized against mouse &#x03B2;-actin, respectively. Analysis of relative expression was performed using the 2(&#x2212;&#x0394;&#x0394;CT) method.</p>
</sec>
<sec id="sec26">
<label>2.6</label>
<title>KM mouse ex vivo colonic organ culture</title>
<p>KM mouse (M group; with 5&#x202F;mg/kg loperamide for 1&#x202F;week; Constipation was diagnosed by insufficient fecal water content, long defecation time, small fecal volume and light weight) sacrificed after anesthesia with pentobarbital sodium. The colon were collected. The feces were removed with sterile syringes in a continuously ventilated (5% CO<sub>2</sub>&#x202F;+&#x202F;95% O<sub>2</sub>) Krebs-Ringer Buffer, and then cut colon into small segments 1&#x202F;cm long. These colonal segments were then cut into sheets and placed in 24-well plates, respectively. Each well contained Krebs-Ringer Buffer continuously ventilated at 37&#x00B0;C and corresponding drug with a final concentration of 10&#x202F;M and a volume of 1&#x202F;ml. The culture was kept at 37&#x00B0;C, 5%CO<sub>2</sub>&#x202F;+&#x202F;95%O<sub>2</sub>, PH 7.4 for 5&#x202F;h, and the tissue status was examined under the microscope every 15&#x202F;min. Further experiments were carried out 5&#x202F;h later.</p>
</sec>
<sec id="sec27">
<label>2.7</label>
<title>Targeting metabolomics</title>
<p>The collected samples were thawed on ice, and metabolite were extracted with 80% methanol Buffer. Briefly, 50&#x202F;mg of sample was extracted with 0.5&#x202F;ml of precooled 80% methanol. The extraction mixture was then stored in 30&#x202F;min at &#x2212;20&#x00B0;C. After centrifugation at 20,000&#x202F;g for 15&#x202F;min, the supernatants were transferred into new tube to and vacuum dried. The samples were redissolved with 100&#x202F;&#x03BC;l 80% methanol and stored at &#x2212;80&#x00B0;C prior to the LC&#x2013;MS analysis. In addition, pooled QC samples were also prepared by combining 10&#x202F;&#x03BC;l of each extraction mixture.</p>
<p>Chromatographic mass spectrometry condition parameters are as follows: Chromatographic column: Waters ACQUITY UPLC BEH C18 (3.0 &#x00D7; 100&#x202F;mm, 1.7&#x202F;&#x03BC;m). Column temperature: 40&#x00B0;C. Sample size: 2&#x202F;&#x03BC;l. Mobile phase: A: primary aqueous solution; B: Methanol: acetonitrile (volume ratio 1:1). The mass spectrum condition parameters are as follows: Sampling mode: MRM mode. See Materials section for standards. The standard curve is shown in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S2</xref>.</p>
</sec>
</sec>
<sec sec-type="results" id="sec28">
<label>3</label>
<title>Results</title>
<sec id="sec29">
<label>3.1</label>
<title>The postbiotic of hawthorn-probiotic metabolites are quite different from the postbiotic of hawthorn and the postbiotic of hawthorn</title>
<p>The TIC (Total Ion Chromotogram) of the metabolites of Lactobacillus (F), postbiotic of hawthorn-probiotic(FS), hawthorn (S) is shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. We found that after fermentation, the FS group was significantly different from the F and S groups in both anion and cationic tests. According to the Mz-rt figrure (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), it can be found that the main detection period of metabolic ions in this test is 0&#x2013;5&#x202F;min, and the main detection m/z is 100&#x2013;500. In this test, there were a total of 12,009 anion peaks and 20,611 cation peaks. The types of metabolic ion peaks are mainly lipids and lipid-like molecules, Organoheterocyclic compounds, Organic acids and derivatives, Benzenoids, Phenylpropanoids and polyketides, and Organic oxygen compounds.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p><bold>(A)</bold> TIC (Total Ion Chromotogram), a superposition of all metabolite strengths of each sample, with the retention time of the liquid chromatography as the horizontal coordinate and the ion strength as the vertical coordinate, reflecting the overall situation of the metabolite peak in the sample. <bold>(B)</bold> Mass-Charge Ratio and Retention time (mz-rt, mass-charge Ratio and Retention time). Each point is a metabolite peak, with the retention time of metabolites as the horizontal coordinate and the mass-charge ratio as the vertical coordinate, reflecting the overall hydrophilicity and molecular weight of all the metabolites in this project. The color of the dots represents the density of the region (the chromatographies are spectral series, red is dense, and blue is sparse). <bold>(C)</bold> Statistical map of metabolite species for first-order molecular weight identification. The figure extracts the classification information of the substance in which the substance is located and performs the number statistics. The horizontal coordinate is the classification and the vertical coordinate is the number of metabolic peaks.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g001.tif"/>
</fig>
<p>After further analysis of primary metabolites (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), we found that group FS integrated some components of group F and group S, and the part with effective increase in content was in the lower right corner of the way. As can be seen from <xref ref-type="fig" rid="fig2">Figures 2B</xref>&#x2013;<xref ref-type="fig" rid="fig2">D</xref>, the differences within the test group were small, while the differences between the groups were large, and the biological repeatability was relatively good.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p><bold>(A)</bold> Heatmap of metabolite intensity. Each column has a sample, each behavior has a displacement peak, and the color represents the intensity information (Log10 value). <bold>(B)</bold> Pairwise correlation heat map of samples. Pairwise sample correlation analysis was performed using all metabolic intensity of each sample. The upper right part of the figure shows the correlation coefficient, and the lower left part of the figure shows the degree of correlation fitting with an ellipse. <bold>(C)</bold> Principal component score chart. For PCA analysis of detected substances and identified metabolites, PCA score plot mainly represents the distribution trend of data points, each point in the graph represents a sample, and the similarities and differences between all samples are reflected in the separation trend or aggregation degree of samples in the score plot. The aggregation of points indicates that the observed variables have a high degree of similarity, and the dispersion of points indicates that the observed variables have obvious differences. <bold>(D)</bold> Biorepeat CV cumulative map. The difference coefficients of all replicates under each phenotype were calculated, and the cumulative statistics of each difference coefficient were carried out to show the repeated differences of different phenotypes. The horizontal coordinate of the CV cumulative curve represents the number of CV, and the vertical coordinate represents the proportion of metabolites smaller than the CV in the total number of metabolites.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g002.tif"/>
</fig>
</sec>
<sec id="sec30">
<label>3.2</label>
<title>The postbiotic of hawthorn-probiotic is more abundant than the postbiotic of hawthorn and the postbiotic of hawthorn</title>
<p>We analyzed the secondary metabolites (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) and found that the three groups were still very different. FS/S mainly increased, while FS/F mainly decreased (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). However, in general, the metabolite content of FS was higher than that of F and S (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). As can be seen from <xref ref-type="fig" rid="fig4">Figure 4A</xref>, the difference within the test group is small, while the difference between groups is large, which is close to the real data.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p><bold>(A)</bold> Heatmap of the intensity of metabolites for secondary identification. Quantitative information was extracted from the secondary identified metabolites with high confidence, each of which was classified as a sample, each of which had a metabolic peak, and the color represented the intensity information (Log10 value). <bold>(B)</bold> Univariate analysis of fold-change and <italic>p</italic>-value obtained by T statistical test were used in this project to screen differentially expressed metabolites. Differential ions simultaneously satisfy: ratio &#x003E; 1.5 or ratio &#x003C; 1/1.5; <italic>p</italic> value &#x003C; 0.05. <bold>(C)</bold> VolcanoPlot displays univariate statistical tests using volcanic maps. The horizontal coordinate is the ratio of the mean values of the two phenotypic strengths, and the vertical coordinate is the significance p-value (or corrected <italic>p</italic>-value) of the statistical test, and &#x2212;log10 is taken. The greater the value, the more significant the difference.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g003.tif"/>
</fig>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p><bold>(A)</bold> PLS-DA score plots (left) are used to evaluate the relationships between samples, with the abscissa representing the first principal component and the ordinate representing the second principal component. Each dot represents a sample, and each color represents a phenotype; PLS-DA model check (right). The Permutation test tested whether the PLS-DA model was overfitted with a number of 100. The x-coordinate is the correlation of the Q2 and R2 calculated by the permutation to the original Q2 and R2 values, and the y-coordinate is the R2 and Q2 calculated by each permutation. Pvalue shows the significance of the replacement test, Q2&#x2019;s pvalue&#x003C; 0.05 indicates that the model is not overfitted. <bold>(B)</bold> For metabolites of global correlation in multiple comparison groups, metabolites with differential and secondary identification are extracted, each point of the correlation plot is a metabolite, and the horizontal and vertical coordinates are the ratio (logarithm) of each comparison group. <bold>(C)</bold> Multi-group secondary K clustering. The HMDB classification information was extracted from the metabolites identified by differential ions, and the metabolites were classified and counted for each expression category.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g004.tif"/>
</fig>
<p>With VIP&#x202F;&#x003E;&#x202F;1 and Pvalue &#x003C;0.05, differential secondary metabolites were screened, and <xref ref-type="fig" rid="fig4">Figure 4B</xref> was obtained. Then, K-mean cluster analysis was performed on these differential secondary metabolites (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), and it was found that Organic acids and derivatives, Organoheterocyclic compounds, lipids and lipid-like molecules, Benzenoids, Phenylpropanoids and polyketides are the main rising components of FS, but many components are unknown.</p>
</sec>
<sec id="sec31">
<label>3.3</label>
<title>Network pharmacology and preliminary experiments have found common targets of constipation and postbiotic of hawthorn-probiotic</title>
<p>Then we went on target hunting. Through network pharmacology, we found 20 common targets for metabolic mixtures and constipation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The PPI network between them is plotted (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In the previous study (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), we also found and verified several other targets, including TNF-&#x03B1;, Mucin2, Enac-&#x03B3;, and AQP3. Among them, TNF-&#x03B1; has attracted our attention, and after reviewing the literature, we also included IL-6 and IL-17A in the experiment. By conducting RT-qPCR on the colons of mice in normal group (N), model group (M), and postbiotic of hawthorn-probiotic group (FS), the primers are listed in <xref ref-type="table" rid="tab6">Table 1</xref>. We found that the postbiotic of hawthorn-probiotic was capable of decreasing the expression of NR1I2 and ST1A1 (SULT1A1), and increased the expression of GLP-2r, a receptor for GCG. However, the expression of ABCB1B, NR1I3, IL-6, and IL-17A showed a decreased trend, with no statistical significance (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p><bold>(A)</bold> Venn diagram, common target of constipation and fermentation fluid. <bold>(B)</bold> PPI maps of common targets. <bold>(C)</bold> Flow chart of the preliminary work. <bold>(D)</bold> Changes in target gene expression levels verified by colon RT-qPCR. NS; &#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.05; &#x002A;&#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.01; &#x002A;&#x002A;&#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g005.tif"/>
</fig>
</sec>
<sec id="sec32">
<label>3.4</label>
<title>Molecular docking and molecular dynamics analysis proved that the postbiotic of hawthorn-probiotic target metabolite was stable in binding to the target</title>
<p>We found 131 significantly elevated secondary metabolites (see <xref ref-type="supplementary-material" rid="SM1">Supplementary material</xref>), and then searched for the postbiotic of hawthorn-probiotic that was significantly higher (VIP&#x202F;&#x003E;&#x202F;1.2, FC&#x202F;&#x003E;&#x202F;2or&#x202F;&#x003C;&#x202F;0.5, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.01). We then used 112 metabolites for which we found a clear chemical structure to intermingle with previously screened targets (AQP3, Enac-&#x03B3;, SULT1A1, TNF) and those we are still interested in (IL17A, IL6R). NR1I2 was found in the nucleus, and we did not focus on this target because we had no evidence that our metabolites could enter the nucleus. Subsequently, we found (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) that these metabolites are generally combined with SULT1A1 and TNF. They bind well to parts of AQP3, GLP-2R, Enac-&#x03B3; (SCNIG), and IL17A. But they do not combine well with IL6R. We used the index of binding energy to sort from large to small, and selected the top 10 compounds in each target for presentation (<xref ref-type="table" rid="tab7">Table 2</xref>). Then, we combined the best groups and visualized them (<xref ref-type="fig" rid="fig6">Figures 6B</xref>&#x2013;<xref ref-type="fig" rid="fig6">G</xref>). These are TNF-Baicalin, AQP3-Quinacridone, Enac&#x03B3;-Quinacridone, IL17A-Baicalin, SULT1A1-N-Phenyl-2 naphthylamine, GLP2R-L-Isoleucine. We also performed molecular dynamics analysis on them (<xref ref-type="fig" rid="fig7">Figure 7</xref>). The results of RMSD, RMSF, and RG of the above small molecules and targets were all good.</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p><bold>(A)</bold> Heat maps of binding energies of 112 secondary metabolites to 7 targets. Visualization of the combination with the highest binding energy of the <bold>(B&#x2013;G)</bold> secondary metabolite and target protein.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g006.tif"/>
</fig>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p><bold>(A&#x2013;F)</bold> Visualization of molecular dynamics analysis results of the combination with the highest binding energy of secondary metabolites and target proteins.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g007.tif"/>
</fig>
</sec>
<sec id="sec33">
<label>3.5</label>
<title>Ex vivo colonic organ culture demonstrated that the target metabolite can be effective by loperamide to model the corresponding target of mouse colon</title>
<p>We tried our best to purchase the 11 compounds that were virtually screened (Quinacridone, vitexin-2 &#x201C;-o-rhamnoside, L-Isoleucine, Baicalin, Exemestane, Hyperoside, Quercetin, Apigenin, N-Phenyl-2-naphthylamine, Genistein, Daidzein. See the Materials section for specific information), and the colons of loperamide modeled mice were removed for experiments. Finally, we found (<xref ref-type="fig" rid="fig8">Figure 8</xref>) that in general, the compound regulated the intestinal targets of the model mice in a favorable direction, especially Enac-&#x03B3;. However, some compounds resulted in increased expression of the target, and there is a worsening trend. Daidzein, for example, increased TNF expression.</p>
<fig position="float" id="fig8">
<label>Figure 8</label>
<caption>
<p><bold>(A&#x2013;E)</bold> <italic>In vitro</italic> experiments to verify the gene expression levels of the compound&#x2014;target protein combinations with higher binding energy. NS; &#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.05; &#x002A;&#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.01; &#x002A;&#x002A;&#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g008.tif"/>
</fig>
</sec>
<sec id="sec34">
<label>3.6</label>
<title>Targeted metabolomics found that postbiotic of hawthorn-probiotic regulated short chain fatty acids metabolism in the gut of loperamide modelled mice</title>
<p>So we found that the postbiotic of hawthorn-probiotic regulated the gut microbiome structure of loperamide in mice and their ability to produce biofilms (<xref ref-type="bibr" rid="ref13">13</xref>). So we conducted targeted metabolomic analysis on feces, and we found (<xref ref-type="fig" rid="fig9">Figure 9A</xref>) that the short chain fatty acids profiling of normal group (N), model group (M), postbiotic of hawthorn-probiotic (FS) was completely different. The three groups had good differentiation and intra-group repeatability (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). By analyzing short chain fatty acids separately (<xref ref-type="fig" rid="fig9">Figures 9C</xref>&#x2013;<xref ref-type="fig" rid="fig9">I</xref>), Butyric acid and Propionic acid contents rise significantly in the intestine of constipated mice, while Isovaleric acid and Hexanoic acid contents decline. The postbiotic of hawthorn-probiotic can reduce Butyric acid content to normal level, and it can also increase Valeric acid and Isobutyric acid content. However, Acetic acid and Propionic acid did not change significantly.</p>
<fig position="float" id="fig9">
<label>Figure 9</label>
<caption>
<p><bold>(A)</bold> Heat maps of various short chain fatty acids contents in feces of KM mice in groups N, M and FS. <bold>(B)</bold> PCA plots of the three groups. <bold>(C&#x2013;I)</bold> Bar chart for the comparison of various short chain fatty acids contents in the three groups. NS; &#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.05; &#x002A;&#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.01; &#x002A;&#x002A;&#x002A;<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001.</p>
</caption>
<graphic xlink:href="fnut-12-1498004-g009.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec35">
<label>4</label>
<title>Discussion</title>
<p>With the exacerbation of population aging, constipation, a common gastrointestinal disease, is receiving increasing attention. As a novel approach, post-biotics are being studied in many diseases, including constipation. In our preliminary research (<xref ref-type="bibr" rid="ref13">13</xref>), aged KM mice were modeled with loperamide, and we found that the postbiotic combination of hawthorn-probiotic was safe and effective. It alleviated intestinal water-sodium metabolism and chronic inflammation, promoted cell proliferation, and reduced apoptosis. By inhibiting harmful bacterial colonization, increasing the abundance of probiotics, and maintaining intestinal microbiota, it improved the gut microbiome. In this study, we observed an increase in the content of some secondary metabolites compared to hawthorn or probiotic alone. Through network pharmacology and mouse colonic tissue analysis, we identified new targets, particularly SULT1A1 and GLP-2r. Subsequently, molecular docking, molecular dynamics analysis, and <italic>in vitro</italic> experiments using colonic tissue from KM mice revealed stable binding between targets and secondary metabolites, especially TNF-Baicalin, AQP3-Quinacridone, Enac&#x03B3;-Quinacridone, IL17A-Baicalin, SULT1A1-N-Phenyl-2 naphthylamine, and GLP2R-L-Isoleucine. Furthermore, short chain fatty acids metabolism analysis of feces from KM mice in this experiment indicated that the hawthorn-probiotic postbiotic improved short chain fatty acid profiling.</p>
<p>SULT1A1 is a sulfotransferase enzyme that participates in the metabolism and detoxification (<xref ref-type="bibr" rid="ref15">15</xref>, <xref ref-type="bibr" rid="ref16">16</xref>) processes of various endogenous and exogenous compounds within the body (<xref ref-type="bibr" rid="ref17">17</xref>). Its primary function involves conjugating electrophilic compounds with water-soluble sulfate substrates, thereby increasing their water solubility and facilitating their excretion from the body. In terms of research progress, SULT1A1 has been extensively studied and demonstrated significant roles in numerous fields (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref19">19</xref>). For instance, in cancer research, the expression levels of SULT1A1 are closely associated with the occurrence and progression of tumors (<xref ref-type="bibr" rid="ref20">20</xref>, <xref ref-type="bibr" rid="ref21">21</xref>), including colorectal cancer, by influencing tumor growth and metastasis through the regulation of endogenous hormone and carcinogen metabolism (<xref ref-type="bibr" rid="ref17">17</xref>). Additionally, in drug metabolism and toxicology studies, SULT1A1 is also considered as one of the crucial enzymes involved in drug metabolism and detoxification, exerting significant effects on the metabolic pathways of many drugs and the formation of toxic metabolites (<xref ref-type="bibr" rid="ref15">15</xref>). We found that the expression level of SULT1A1 in postbiotic of hawthorn-probiotic (FS) was lower than that in constipation model (M). This showed that the intestines of mice in FS group recovered and almost no toxins needed to be excreted.</p>
<p>GLP-2r, the receptor for the intestinal hormone glucagon-like peptide-2 (GLP-2), is widely expressed in intestinal tissues (<xref ref-type="bibr" rid="ref22">22</xref>). GLP-2 is a gastrointestinal hormone secreted by enteroendocrine cells in the intestine (<xref ref-type="bibr" rid="ref23">23</xref>), and its primary function is to promote proliferation and repair of intestinal mucosal cells, increase mucosal cell survival, while reducing intestinal motility and secretion (<xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref24">24</xref>). These effects contribute to maintaining the integrity of the intestinal mucosa and promoting intestinal health. In terms of research progress, GLP-2r has been extensively studied and has shown potential roles in the treatment of various intestinal-related diseases. For example, GLP-2r agonists have been used in the treatment of inflammatory bowel diseases (such as Crohn&#x2019;s disease and ulcerative colitis) (<xref ref-type="bibr" rid="ref25">25</xref>) because they can promote intestinal mucosal repair and regeneration, improving patients&#x2019; symptoms and quality of life. Additionally, GLP-2r agonists are also being investigated for the treatment of other intestinal disorders such as intestinal fistulas and short bowel syndrome (<xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref24">24</xref>). We found that the postbiotic of hawthorn-probiotic mice had elevated GLP-2r expression in colon. In previous studies, we observed by CCK8 and flow cytometry that postbiotic of hawthorn-probiotic promoted intestinal epithelial cell proliferation and reduced apoptosis. These suggest that the postbiotic of hawthorn-probiotic secondary metabolites bind to GLP-2r, promoting intestinal cell proliferation, reducing intestinal cell apoptosis, and restoring intestinal barrier function.</p>
<p>IL-17A is a cytokine belonging to the IL-17 family, primarily produced by T cells and other immune cells such as NK cells and lymphocytes (<xref ref-type="bibr" rid="ref26">26</xref>), serving as a crucial inflammatory mediator (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref28">28</xref>). It plays key roles in immune regulation, inflammatory responses (<xref ref-type="bibr" rid="ref29">29</xref>) (particularly against bacterial and fungal infections (<xref ref-type="bibr" rid="ref30">30</xref>)), and tissue repair (<xref ref-type="bibr" rid="ref31">31</xref>). Inhibitors of IL-17A and its receptor have emerged as important targets for the treatment of autoimmune diseases (such as rheumatoid arthritis, psoriasis, etc.) and inflammatory bowel diseases (<xref ref-type="bibr" rid="ref26">26</xref>). Relevant drugs have been developed and entered clinical trial phases. We found that the postbiotic of hawthorn-probiotic (FS) group had reduced IL-17A expression in colon tissue. So this suggests that the postbiotic of hawthorn-probiotic secondary metabolites are capable of reducing inflammation in the gut. Our previous studies found that postbiotic of hawthorn-probiotic could improve intestinal flora structure and short chain fatty acids metabolism in elderly constipated mice. IL-17A plays an important role in this.</p>
<p>In conclusion, our study once again proves that postbiotic of hawthorn-probiotic is beneficial to senile constipation, and the key secondary metabolites and targets are found and preliminarily verified. Our findings can be used as a reference for the treatment of constipation and other intestinal disorders.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec36">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec sec-type="ethics-statement" id="sec37">
<title>Ethics statement</title>
<p>The animal study was approved by 240&#x202F;days old, male KM mice obtained from the Guangzhou Regal Biotechnology Co., Ltd., (SCXK [Yue] 20180182, SYXK [Yue] 2021-0059) were pair-housed in plastic cages in a temperature-controlled (25&#x202F;&#x00B1;&#x202F;2&#x00B0;C) colony room under a 12/12-h light/dark cycle, with free access to food and water. All experimental protocols were approved by the Animal Center, Guangzhou University of Chinese Medicine. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec38">
<title>Author contributions</title>
<p>YW: Conceptualization, Data curation, Methodology, Project administration, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. SC: Formal analysis, Methodology, Software, Writing &#x2013; original draft. YL: Formal analysis, Validation, Writing &#x2013; original draft. WW: Project administration, Resources, Supervision, Writing &#x2013; review &#x0026; editing. YH: Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing &#x2013; review &#x0026; editing.</p>
</sec>
<sec sec-type="funding-information" id="sec39">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by grants from the Chinese National Natural Science Foundation (Grant no.: 31700288) and the University - Hospital Joint Fund Project of Guangzhou University of Chinese Medicine (GZYSE2024U05).</p>
</sec>
<ack>
<p>I would like to thank the School of Basic Medicine of Guangzhou University of Chinese Medicine for providing the experimental platform. Thank you to Chen Yongjie from servicebio for his fast delivery of experimental reagents.</p>
</ack>
<sec sec-type="COI-statement" id="sec40">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="sec41">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec42">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fnut.2025.1498004/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnut.2025.1498004/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.pdf" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn id="fn0001"><p><sup>1</sup><ext-link xlink:href="https://www.uniprot.org/" ext-link-type="uri">https://www.uniprot.org/</ext-link></p></fn>
<fn id="fn0002"><p><sup>2</sup><ext-link xlink:href="https://www1.rcsb.org/" ext-link-type="uri">https://www1.rcsb.org/</ext-link></p></fn>
<fn id="fn0003"><p><sup>3</sup><ext-link xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link></p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname> <given-names>P</given-names></name> <name><surname>O'Mahony</surname> <given-names>D</given-names></name></person-group>. <article-title>Constipation in old age</article-title>. <source>Best Pract Res Clin Gastroenterol</source>. (<year>2009</year>) <volume>23</volume>:<fpage>875</fpage>&#x2013;<lpage>87</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bpg.2009.09.001</pub-id>, PMID: <pub-id pub-id-type="pmid">19942165</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barbara</surname> <given-names>G</given-names></name> <name><surname>Barbaro</surname> <given-names>MR</given-names></name> <name><surname>Marasco</surname> <given-names>G</given-names></name> <name><surname>Cremon</surname> <given-names>C</given-names></name></person-group>. <article-title>Chronic constipation: from pathophysiology to management</article-title>. <source>Minerva Gastroenterol (Torino)</source>. (<year>2023</year>) <volume>69</volume>:<fpage>277</fpage>&#x2013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.23736/S2724-5985.22.03335-6</pub-id>, PMID: <pub-id pub-id-type="pmid">36727654</pub-id></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broad</surname> <given-names>J</given-names></name> <name><surname>Kung</surname> <given-names>V</given-names></name> <name><surname>Palmer</surname> <given-names>A</given-names></name> <name><surname>Elahi</surname> <given-names>S</given-names></name> <name><surname>Karami</surname> <given-names>A</given-names></name> <name><surname>Darreh-Shori</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Changes in neuromuscular structure and functions of human colon during ageing are region-dependent</article-title>. <source>Gut</source>. (<year>2019</year>) <volume>68</volume>:<fpage>1210</fpage>&#x2013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2018-316279</pub-id>, PMID: <pub-id pub-id-type="pmid">30228216</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname> <given-names>M</given-names></name> <name><surname>Lee</surname> <given-names>JS</given-names></name> <name><surname>Viramontes</surname> <given-names>B</given-names></name> <name><surname>Bharucha</surname> <given-names>AE</given-names></name> <name><surname>Tangalos</surname> <given-names>EG</given-names></name></person-group>. <article-title>Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people</article-title>. <source>J Am Geriatr Soc</source>. (<year>2000</year>) <volume>48</volume>:<fpage>1142</fpage>&#x2013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1532-5415.2000.tb04793.x</pub-id>, PMID: <pub-id pub-id-type="pmid">10983917</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Mahony</surname> <given-names>D</given-names></name> <name><surname>O'Leary</surname> <given-names>P</given-names></name> <name><surname>Quigley</surname> <given-names>EM</given-names></name></person-group>. <article-title>Aging and intestinal motility: a review of factors that affect intestinal motility in the aged</article-title>. <source>Drugs Aging</source>. (<year>2002</year>) <volume>19</volume>:<fpage>515</fpage>&#x2013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.2165/00002512-200219070-00005</pub-id>, PMID: <pub-id pub-id-type="pmid">12182688</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J</given-names></name> <name><surname>Chai</surname> <given-names>X</given-names></name> <name><surname>Zhao</surname> <given-names>F</given-names></name> <name><surname>Hou</surname> <given-names>G</given-names></name> <name><surname>Meng</surname> <given-names>Q</given-names></name></person-group>. <article-title>Food applications and potential health benefits of hawthorn</article-title>. <source>Food Secur</source>. (<year>2022</year>) <volume>11</volume>:<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.3390/foods11182861</pub-id>, PMID: <pub-id pub-id-type="pmid">36140986</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname> <given-names>AC</given-names></name> <name><surname>Quigley</surname> <given-names>EMM</given-names></name> <name><surname>Lacy</surname> <given-names>BE</given-names></name> <name><surname>Lembo</surname> <given-names>AJ</given-names></name> <name><surname>Saito</surname> <given-names>YA</given-names></name> <name><surname>Schiller</surname> <given-names>LR</given-names></name> <etal/></person-group>. <article-title>Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis</article-title>. <source>Am J Gastroenterol</source>. (<year>2014</year>) <volume>109</volume>:<fpage>1547</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ajg.2014.202</pub-id>, PMID: <pub-id pub-id-type="pmid">25070051</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bazzocchi</surname> <given-names>G</given-names></name> <name><surname>Giovannini</surname> <given-names>T</given-names></name> <name><surname>Giussani</surname> <given-names>C</given-names></name> <name><surname>Brigidi</surname> <given-names>P</given-names></name> <name><surname>Turroni</surname> <given-names>S</given-names></name></person-group>. <article-title>Effect of a new synbiotic supplement on symptoms, stool consistency, intestinal transit time and gut microbiota in patients with severe functional constipation: a pilot randomized double-blind, controlled trial</article-title>. <source>Tech Coloproctol</source>. (<year>2014</year>) <volume>18</volume>:<fpage>945</fpage>&#x2013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10151-014-1201-5</pub-id>, PMID: <pub-id pub-id-type="pmid">25091346</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname> <given-names>LW</given-names></name> <name><surname>Luciana</surname> <given-names>CL</given-names></name> <name><surname>Amanda</surname> <given-names>FB</given-names></name> <name><surname>Raquel</surname> <given-names>ST</given-names></name> <name><surname>Glaucia</surname> <given-names>MS</given-names></name> <name><surname>Natalia</surname> <given-names>PP</given-names></name> <etal/></person-group>. <article-title>Effect of synbiotic in constipated adult women &#x2013; a randomized, double-blind, placebo-controlled study of clinical response</article-title>. <source>Clin Nutr</source>. (<year>2013</year>) <volume>32</volume>:<fpage>27</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clnu.2012.08.010</pub-id>, PMID: <pub-id pub-id-type="pmid">22959620</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname> <given-names>JL</given-names></name> <name><surname>Rosita</surname> <given-names>J</given-names></name> <name><surname>Abu</surname> <given-names>SH</given-names></name> <name><surname>Jin</surname> <given-names>YC</given-names></name></person-group>. <article-title>Effects of Synbiotics among constipated adults in Serdang, Selangor, Malaysia&#x2014;a randomised, double-blind, placebo-controlled trial</article-title>. <source>Nutrients</source>. (<year>2018</year>) <volume>10</volume>:<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu10070824</pub-id>, PMID: <pub-id pub-id-type="pmid">29949873</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linetzky</surname> <given-names>WD</given-names></name> <name><surname>Alves</surname> <given-names>PCC</given-names></name> <name><surname>Logullo</surname> <given-names>L</given-names></name> <name><surname>Manzoni</surname> <given-names>JT</given-names></name> <name><surname>Almeida</surname> <given-names>D</given-names></name> <name><surname>Teixeira</surname> <given-names>DSML</given-names></name> <etal/></person-group>. <article-title>Microbiota benefits after inulin and partially hydrolized guar gum supplementation: a randomized clinical trial in constipated women</article-title>. <source>Nutr Hosp</source>. (<year>2012</year>) <volume>27</volume>:<fpage>123</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1590/S0212-16112012000100014</pub-id>, PMID: <pub-id pub-id-type="pmid">22566311</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname> <given-names>K</given-names></name> <name><surname>Mozhgan</surname> <given-names>S</given-names></name></person-group>. <article-title>Role of Synbiotics in the treatment of childhood constipation: a double-blind randomized placebo controlled trial</article-title>. <source>Iran J Pediatr</source>. (<year>2010</year>) <volume>20</volume>:<fpage>387</fpage>&#x2013;<lpage>92</lpage>. PMID: <pub-id pub-id-type="pmid">23056736</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>Y</given-names></name> <name><surname>Huang</surname> <given-names>N</given-names></name> <name><surname>Ye</surname> <given-names>X</given-names></name> <name><surname>Liu</surname> <given-names>M</given-names></name> <name><surname>Wei</surname> <given-names>M</given-names></name> <name><surname>Huang</surname> <given-names>Y</given-names></name></person-group>. <article-title>The postbiotic of hawthorn-probiotic ameliorating constipation caused by loperamide in elderly mice by regulating intestinal microecology</article-title>. <source>Front Nutr</source>. (<year>2023</year>) <volume>10</volume>:<fpage>1103463</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2023.1103463</pub-id>, PMID: <pub-id pub-id-type="pmid">37006920</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname> <given-names>WB</given-names></name> <name><surname>Broadhurst</surname> <given-names>D</given-names></name> <name><surname>Begley</surname> <given-names>P</given-names></name> <name><surname>Zelena</surname> <given-names>E</given-names></name> <name><surname>Francis-McIntyre</surname> <given-names>S</given-names></name> <name><surname>Anderson</surname> <given-names>N</given-names></name> <etal/></person-group>. <article-title>Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry</article-title>. <source>Nat Protoc</source>. (<year>2011</year>) <volume>6</volume>:<fpage>1060</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nprot.2011.335</pub-id>, PMID: <pub-id pub-id-type="pmid">21720319</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname> <given-names>I</given-names></name> <name><surname>Wang</surname> <given-names>T</given-names></name> <name><surname>Leyh</surname> <given-names>TS</given-names></name></person-group>. <article-title>Isoform-specific therapeutic control of sulfonation in humans</article-title>. <source>Biochem Pharmacol</source>. (<year>2019</year>) <volume>159</volume>:<fpage>25</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2018.11.010</pub-id>, PMID: <pub-id pub-id-type="pmid">30423313</pub-id></citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tyapochkin</surname> <given-names>E</given-names></name> <name><surname>Kumar</surname> <given-names>VP</given-names></name> <name><surname>Cook</surname> <given-names>PF</given-names></name> <name><surname>Chen</surname> <given-names>G</given-names></name></person-group>. <article-title>Reaction product affinity regulates activation of human sulfotransferase 1A1 PAP sulfation</article-title>. <source>Arch Biochem Biophys</source>. (<year>2011</year>) <volume>506</volume>:<fpage>137</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.abb.2010.11.018</pub-id>, PMID: <pub-id pub-id-type="pmid">21111704</pub-id></citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>H</given-names></name> <name><surname>Morris</surname> <given-names>JS</given-names></name> <name><surname>Li</surname> <given-names>Y</given-names></name> <name><surname>Doll</surname> <given-names>MA</given-names></name> <name><surname>Hein</surname> <given-names>DW</given-names></name> <name><surname>Liu</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer</article-title>. <source>Carcinogenesis</source>. (<year>2008</year>) <volume>29</volume>:<fpage>1184</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1093/carcin/bgn085</pub-id>, PMID: <pub-id pub-id-type="pmid">18499698</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pietrauszka</surname> <given-names>K</given-names></name> <name><surname>Bergler-Czop</surname> <given-names>B</given-names></name></person-group>. <article-title>Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review</article-title>. <source>Postepy Dermatol Alergol</source>. (<year>2022</year>) <volume>39</volume>:<fpage>472</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.5114/ada.2020.99947</pub-id>, PMID: <pub-id pub-id-type="pmid">35950120</pub-id></citation></ref>
<ref id="ref19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname> <given-names>S</given-names></name> <name><surname>Gangwar</surname> <given-names>A</given-names></name> <name><surname>Patir</surname> <given-names>H</given-names></name> <name><surname>Bhargava</surname> <given-names>K</given-names></name> <name><surname>Ahmad</surname> <given-names>Y</given-names></name></person-group>. <article-title>Reverse translating SULT1A1, a potential biomarker in roentgenographically tested rat model of rapid HAPE induction</article-title>. <source>Life Sci</source>. (<year>2019</year>) <volume>229</volume>:<fpage>132</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2019.05.035</pub-id>, PMID: <pub-id pub-id-type="pmid">31100325</pub-id></citation></ref>
<ref id="ref20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>L</given-names></name> <name><surname>Shen</surname> <given-names>W</given-names></name> <name><surname>Davis</surname> <given-names>MI</given-names></name> <name><surname>Kong</surname> <given-names>K</given-names></name> <name><surname>Vu</surname> <given-names>P</given-names></name> <name><surname>Saha</surname> <given-names>SK</given-names></name> <etal/></person-group>. <article-title>SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers</article-title>. <source>Nat Can</source>. (<year>2023</year>) <volume>4</volume>:<fpage>365</fpage>&#x2013;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s43018-023-00523-0</pub-id>, PMID: <pub-id pub-id-type="pmid">36914816</pub-id></citation></ref>
<ref id="ref21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname> <given-names>SS</given-names></name> <name><surname>Koifman</surname> <given-names>RJ</given-names></name> <name><surname>Ferreira</surname> <given-names>RM</given-names></name> <name><surname>Diniz</surname> <given-names>LF</given-names></name> <name><surname>Brennan</surname> <given-names>P</given-names></name> <name><surname>Boffetta</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>SULT1A1 genetic polymorphisms and the association between smoking and oral cancer in a case-control study in Brazil</article-title>. <source>Front Oncol</source>. (<year>2012</year>) <volume>2</volume>:<fpage>183</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2012.00183</pub-id>, PMID: <pub-id pub-id-type="pmid">23264952</pub-id></citation></ref>
<ref id="ref22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>W</given-names></name> <name><surname>Wang</surname> <given-names>K</given-names></name> <name><surname>Zhao</surname> <given-names>Z</given-names></name> <name><surname>Mao</surname> <given-names>Q</given-names></name> <name><surname>Wang</surname> <given-names>G</given-names></name> <name><surname>Li</surname> <given-names>Q</given-names></name> <etal/></person-group>. <article-title>Exosomes-mediated transfer of miR-125a/b in cell-to-cell communication: a novel mechanism of genetic exchange in the intestinal microenvironment</article-title>. <source>Theranostics</source>. (<year>2020</year>) <volume>10</volume>:<fpage>7561</fpage>&#x2013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.7150/thno.41802</pub-id>, PMID: <pub-id pub-id-type="pmid">32685005</pub-id></citation></ref>
<ref id="ref23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>SJ</given-names></name> <name><surname>Lee</surname> <given-names>J</given-names></name> <name><surname>Li</surname> <given-names>KK</given-names></name> <name><surname>Holland</surname> <given-names>D</given-names></name> <name><surname>Maughan</surname> <given-names>H</given-names></name> <name><surname>Guttman</surname> <given-names>DS</given-names></name> <etal/></person-group>. <article-title>Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis</article-title>. <source>Endocrinology</source>. (<year>2012</year>) <volume>153</volume>:<fpage>1141</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1210/en.2011-1954</pub-id>, PMID: <pub-id pub-id-type="pmid">22253424</pub-id></citation></ref>
<ref id="ref24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname> <given-names>K</given-names></name> <name><surname>Imam</surname> <given-names>NA</given-names></name> <name><surname>Pintar</surname> <given-names>JE</given-names></name> <name><surname>Brubaker</surname> <given-names>PL</given-names></name></person-group>. <article-title>IGF binding protein-4 is required for the growth effects of glucagon-like peptide-2 in murine intestine</article-title>. <source>Endocrinology</source>. (<year>2015</year>) <volume>156</volume>:<fpage>429</fpage>&#x2013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1210/en.2014-1829</pub-id>, PMID: <pub-id pub-id-type="pmid">25514089</pub-id></citation></ref>
<ref id="ref25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shinzaki</surname> <given-names>S</given-names></name> <name><surname>Sato</surname> <given-names>T</given-names></name> <name><surname>Fukui</surname> <given-names>H</given-names></name></person-group>. <article-title>Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation</article-title>. <source>J Gastroenterol</source>. (<year>2023</year>) <volume>58</volume>:<fpage>598</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00535-023-01983-y</pub-id>, PMID: <pub-id pub-id-type="pmid">36961556</pub-id></citation></ref>
<ref id="ref26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akitsu</surname> <given-names>A</given-names></name> <name><surname>Iwakura</surname> <given-names>Y</given-names></name></person-group>. <article-title>Interleukin-17-producing gammadelta T (gammadelta17) cells in inflammatory diseases</article-title>. <source>Immunology</source>. (<year>2018</year>) <volume>155</volume>:<fpage>418</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1111/imm.12993</pub-id>, PMID: <pub-id pub-id-type="pmid">30133701</pub-id></citation></ref>
<ref id="ref27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>SH</given-names></name> <name><surname>Ye</surname> <given-names>XQ</given-names></name> <name><surname>Iwakura</surname> <given-names>Y</given-names></name></person-group>. <article-title>Interleukin-17 family members in health and disease</article-title>. <source>Int Immunol</source>. (<year>2021</year>) <volume>33</volume>:<fpage>723</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxab075</pub-id>, PMID: <pub-id pub-id-type="pmid">34611705</pub-id></citation></ref>
<ref id="ref28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGeachy</surname> <given-names>MJ</given-names></name> <name><surname>Cua</surname> <given-names>DJ</given-names></name> <name><surname>Gaffen</surname> <given-names>SL</given-names></name></person-group>. <article-title>The IL-17 family of cytokines in health and disease</article-title>. <source>Immunity</source>. (<year>2019</year>) <volume>50</volume>:<fpage>892</fpage>&#x2013;<lpage>906</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.021</pub-id>, PMID: <pub-id pub-id-type="pmid">30995505</pub-id></citation></ref>
<ref id="ref29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grizotte-Lake</surname> <given-names>M</given-names></name> <name><surname>Zhong</surname> <given-names>G</given-names></name> <name><surname>Duncan</surname> <given-names>K</given-names></name> <name><surname>Kirkwood</surname> <given-names>J</given-names></name> <name><surname>Iyer</surname> <given-names>N</given-names></name> <name><surname>Smolenski</surname> <given-names>I</given-names></name> <etal/></person-group>. <article-title>Commensals suppress intestinal epithelial cell retinoic acid synthesis to regulate Interleukin-22 activity and prevent microbial Dysbiosis</article-title>. <source>Immunity</source>. (<year>2018</year>) <volume>49</volume>:<fpage>1103</fpage>&#x2013;<lpage>1115.e6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2018.11.018</pub-id>, PMID: <pub-id pub-id-type="pmid">30566883</pub-id></citation></ref>
<ref id="ref30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname> <given-names>HR</given-names></name> <name><surname>Bruno</surname> <given-names>VM</given-names></name> <name><surname>Childs</surname> <given-names>EE</given-names></name> <name><surname>Daugherty</surname> <given-names>S</given-names></name> <name><surname>Hunter</surname> <given-names>JP</given-names></name> <name><surname>Mengesha</surname> <given-names>BG</given-names></name> <etal/></person-group>. <article-title>IL-17 receptor signaling in Oral epithelial cells is critical for protection against oropharyngeal candidiasis</article-title>. <source>Cell Host Microbe</source>. (<year>2016</year>) <volume>20</volume>:<fpage>606</fpage>&#x2013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2016.10.001</pub-id>, PMID: <pub-id pub-id-type="pmid">27923704</pub-id></citation></ref>
<ref id="ref31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x00F6;bel</surname> <given-names>K</given-names></name> <name><surname>Pankratz</surname> <given-names>S</given-names></name> <name><surname>Asaridou</surname> <given-names>CM</given-names></name> <name><surname>Herrmann</surname> <given-names>AM</given-names></name> <name><surname>Bittner</surname> <given-names>S</given-names></name> <name><surname>Merker</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells</article-title>. <source>Nat Commun</source>. (<year>2016</year>) <volume>7</volume>:<fpage>11626</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms11626</pub-id>, PMID: <pub-id pub-id-type="pmid">27188843</pub-id></citation></ref>
</ref-list>
</back>
</article>